Clinical Trials - Capricor

Through its clinical trials, Capricor Therapeutics is actively engaged in the development of novel therapeutics to prevent and treat serious diseases.

INSPIRE

Initiated

Capricor’s Phase 2 INSPIRE study will enroll patients who have a confirmed diagnosis of SARS-CoV-2.

HOPE-2

Completed

Capricor completed the HOPE-2 clinical trial for Capricor’s lead investigational therapy, CAP-1002.

HOPE

PHASE I/II enrollment complete

The Halt cardiomyOPathy progrEssion in Duchenne (HOPE) Phase I/II trial will evaluate CAP-1002 in patients with Duchenne muscular dystrophy associated cardiomyopathy.

ALLSTAR

PHASE I completed

PHASE II enrollment complete

The ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial is a Phase I/II trial evaluating the safety and efficacy of lead therapeutic candidate, CAP-1002 – Capricor’s allogeneic, off-the-shelf, cardiosphere-derived cell product.

DYNAMIC

PHASE I completed

The Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) Phase I trial evaluated CAP-1002 in patients with advanced heart failure.

Go to top